Paladin, Quest Pharma deal

Quest acquired five mAbs against cancer antigens from Paladin for $37,500 in cash and 1.5 million shares valued at $75,000 based on Quest's close of $0.05 on Sept. 29, the day before the deal was announced. Paladin will receive a second payment of 1.5 million shares by Dec. 31, 2010, and is eligible for a further 2 million shares contingent upon future financings by Quest, plus single-digit royalties. ...